These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19935897)

  • 1. Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
    Chudasama HP; Bhatt PA
    Can J Physiol Pharmacol; 2009 Nov; 87(11):900-7. PubMed ID: 19935897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
    Stock MJ
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S25-9. PubMed ID: 9130038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression.
    Gehlert DR; Rasmussen K; Shaw J; Li X; Ardayfio P; Craft L; Coskun T; Zhang HY; Chen Y; Witkin JM
    J Pharmacol Exp Ther; 2009 May; 329(2):429-38. PubMed ID: 19182070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
    Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations.
    Baranowska B; Wolińska-Witort E; Martyńska L; Chmielowska M; Mazurczak-Pluta T; Boguradzka A; Baranowska-Bik A
    Neuro Endocrinol Lett; 2005 Dec; 26(6):675-9. PubMed ID: 16380708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
    Jackson HC; Needham AM; Hutchins LJ; Mazurkiewicz SE; Heal DJ
    Br J Pharmacol; 1997 Aug; 121(8):1758-62. PubMed ID: 9283714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.
    Fisas A; Codony X; Romero G; Dordal A; Giraldo J; Mercé R; Holenz J; Vrang N; Sørensen RV; Heal D; Buschmann H; Pauwels PJ
    Br J Pharmacol; 2006 Aug; 148(7):973-83. PubMed ID: 16783408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
    Hansen G; Jelsing J; Vrang N
    Acta Pharmacol Sin; 2012 Feb; 33(2):194-200. PubMed ID: 22301859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine: a new selective and dual-acting antidepressant.
    Bauer M; Möller HJ; Schneider E
    Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine.
    Liu YL; Heal DJ; Stock MJ
    Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1245-53. PubMed ID: 12187403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
    Nisoli E; Carruba MO
    Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin and norepinephrine reuptake inhibition and eating behavior.
    Hainer V; Kabrnova K; Aldhoon B; Kunesova M; Wagenknecht M
    Ann N Y Acad Sci; 2006 Nov; 1083():252-69. PubMed ID: 17148744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine lost and found.
    Bosello O; Carruba MO; Ferrannini E; Rotella CM
    Eat Weight Disord; 2002 Sep; 7(3):161-7. PubMed ID: 12452247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y.
    Brown M; Bing C; King P; Pickavance L; Heal D; Wilding J
    Br J Pharmacol; 2001 Apr; 132(8):1898-904. PubMed ID: 11309262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
    Aydin N; Topsever P; Kaya A; Karasakal M; Duman C; Dağar A
    Tohoku J Exp Med; 2004 Mar; 202(3):173-80. PubMed ID: 15065643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.